Today: 29 April 2026
Browse Category

NASDAQ:ZYME 17 November 2025

Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals reported positive Phase 3 results for its cancer drug Ziihera in HER2-positive gastroesophageal adenocarcinoma, showing significant improvements in survival endpoints. Jazz shares surged up to 31% pre-market before settling near $141.07 by early afternoon Monday. Ziihera partner Zymeworks saw pre-market gains as high as 59%. The trial enrolled 914 patients across 30 countries.
17 November 2025
···
Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients

Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients

Zymeworks reported its Phase 3 HERIZON-GEA-01 trial showed Ziihera (zanidatamab-hrii) combinations outperformed trastuzumab plus chemotherapy in HER2-positive gastroesophageal adenocarcinoma. The triple-combination arm also improved overall survival. Jazz Pharmaceuticals plans to file for FDA approval in the first half of 2026. ZYME shares jumped 30–50% pre-market on the news.
17 November 2025
····

Stock Market Today

  • Tuya (TUYA) Stock Analysis: Fair Pricing Amid Recent Pullback and Strong Long-Term Gains
    April 29, 2026, 12:05 PM EDT. Tuya (NYSE:TUYA) shares closed at $2.28, down 3.0% in one day and 6.2% over seven days, contrasting with a 3-year total shareholder return of 28.7%. The company reported $321.8 million in annual revenue and $57.9 million net income. Trading at a price-to-earnings (P/E) ratio of 24.1x, Tuya's valuation is slightly above its fair value estimate of 23.5x and peers' average of 21.7x, but below the broader U.S. Software industry average of 30.4x. This reflects investor confidence in its profitability and growth prospects, with earnings expected to grow nearly 10% annually. Risks include dependence on Chinese market demand and relatively rich valuation compared to peers. The stock trades just 0.9% below its intrinsic value according to discounted cash flow (DCF) estimates, suggesting near fair pricing.

Latest article

Mastercard Stock Jumps Before Earnings as Visa’s Big Beat Sends a Fresh Signal

Mastercard Stock Jumps Before Earnings as Visa’s Big Beat Sends a Fresh Signal

29 April 2026
Mastercard shares climbed 3.8% to $526.90 Wednesday after Visa beat profit estimates and raised its outlook, sending Visa shares up 8.7%. Mastercard reports first-quarter results Thursday. The company expanded its Start Path program this week to focus on business payments, with fintech Glass joining to work on public-sector procurement. Mastercard does not lend or issue cards, earning mainly from transaction fees.
GE HealthCare Technologies Inc. Stock Sinks as Tariffs and Chip Costs Force Profit Cut

GE HealthCare Technologies Inc. Stock Sinks as Tariffs and Chip Costs Force Profit Cut

29 April 2026
GE HealthCare cut its 2026 profit forecast Wednesday, citing higher chip, oil, and freight costs, as well as tariffs and a supplier issue. Shares fell nearly 13% to $59.75. First-quarter revenue rose 7.4% to $5.13 billion, but net income dropped to $389 million from $564 million a year earlier. The company also announced a reorganization, merging its Imaging and Advanced Visualization units.
Applied Materials (AMAT) Faces Fresh China Shock After U.S. Targets Hua Hong Shipments

Applied Materials (AMAT) Faces Fresh China Shock After U.S. Targets Hua Hong Shipments

29 April 2026
The U.S. Commerce Department ordered Applied Materials, Lam Research, and KLA to halt some chip-tool shipments to China’s Hua Hong, Reuters reported. The move targets shipments linked to facilities believed capable of advanced chip production. Applied reported $2.10 billion in China revenue last quarter, or 30% of its total. Shares in Applied, Lam, and KLA traded lower after the news.
Go toTop